

1 The Journal of Supercritical Fluids

2

3 **Nanoparticle formation of PVP/astaxanthin inclusion complex by solution-**  
4 **enhanced dispersion by supercritical fluids (SEDS): Effect of PVP and astaxanthin**  
5 **Z-isomer content**

6

7 Kahori Kaga<sup>a</sup>, Masaki Honda<sup>b,\*</sup>, Tomoki Adachi<sup>c</sup>, Masatoshi Honjo<sup>c</sup>, Wahyudiono<sup>a</sup>,  
8 Hideki Kanda<sup>a</sup> and Motonobu Goto<sup>a,\*</sup>

9

10 <sup>a</sup> *Department of Materials Process Engineering, Nagoya University, Furo-cho, Chikusa-*  
11 *ku, Nagoya 464-8603, Japan*

12 <sup>b</sup> *Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-*  
13 *ku, Nagoya 464-8601, Japan*

14 <sup>c</sup> *Research Institute, FANCL Corporation, Kamishinano, Totsuka-ku, Yokohama 244-*  
15 *0806, Japan*

16

17 \*Corresponding author.

18 *E-mail address:* honda@agr.nagoya-u.ac.jp (M. Honda)

19 *E-mail address:* goto.motonobu@material.nagoya-u.ac.jp (M. Goto)

20

21

22

23

1 **Abstract**

2 The effects of operating conditions and Z-isomer content of astaxanthin on coprecipitate  
3 formation of polyvinylpyrrolidone (PVP) and astaxanthin by solution-enhanced  
4 dispersion by supercritical fluids (SEDS) process were investigated. Using this process,  
5 nano-sized (100–200 nm) and water-soluble PVP/astaxanthin inclusion complex was  
6 successfully prepared. As the operating pressure increased from 8 to 15 MPa at a  
7 constant temperature, astaxanthin content in the coprecipitates decreased, and increasing  
8 the operating temperature from 40 to 60 °C at a constant pressure, the particle size and  
9 the astaxanthin content increased. Increasing the PVP ratio for astaxanthin in the range  
10 of 5:1 to 20:1, the particle size decreased and when 10:1 of the ratio, the astaxanthin  
11 content in the coprecipitates was the highest (60 °C, 10 MPa). Additionally, as the Z-  
12 isomer content of astaxanthin increased, the astaxanthin content decreased slightly.  
13 However, the coprecipitates rich in astaxanthin Z-isomers, which have higher  
14 bioavailability and antioxidant capacity, were obtained.

15

16 *Keywords:* Carotenoid, Polyvinylpyrrolidone, Coprecipitation, Supercritical anti-  
17 solvent, *E/Z* isomerization

18

19

20

21

22

23

24

## 1 **1. Introduction**

2 Carotenoids are the most common fat-soluble pigments that give yellow, orange,  
3 and red colors to plants and animals, and more than 750 different types have been  
4 characterized until now [1]. The daily consumption of carotenoids-rich foods would be  
5 beneficial for human health because of the prevention effect of various diseases such as  
6 certain cancers and atherosclerosis as well as high antioxidant capacity [2–4].  
7 Moreover, carotenoids are attracting attention as safe natural colorants in food products  
8 and as an alternative to synthetic colorants which are not well accepted by consumers.

9 Astaxanthin is a keto carotenoid containing 13 conjugated double bonds, and is  
10 found abundantly in the marine world of algae and aquatic animals with a dark-red color  
11 [5]. As with other carotenoids, astaxanthin has high antioxidant capacity and ability to  
12 prevent and treat various diseases such as cancers, chronic inflammatory diseases, and  
13 cardiovascular diseases [4–6]. For these reasons, there is a strong interest in using  
14 astaxanthin as functional and natural colorant in food industry. However, the poor water  
15 solubility of astaxanthin has made its use problematic for food formulations and the  
16 favorable effects of astaxanthin are limited. Furthermore, the low solubility in water of  
17 functional lipid bioactive compounds would be prone to reduce the bioavailability [7,8].  
18 Therefore, it is very important to improve their dispersibility in water by emulsification  
19 for food industry and increment their bioavailability. When preparing carotenoids  
20 dispersions, nano-level particle size is preferable due to the high dispersibility and  
21 bioavailability [9,10].

22 Polyvinylpyrrolidone (PVP; Fig. 1A) is a hydrophilic carrier and has acquired  
23 broad applications in food and pharmaceutical industries [11]. It has the effect of  
24 suppressing crystal growth of compounds with high crystallinity [12] and can improve

1 the solubility of poorly water-soluble compounds [13]. In addition, since PVP contains a  
2 proton acceptor, it is able to form H-bonds with a proton donator group [14,15]. The H-  
3 bonding enhances the extent of interaction between the proton donator and PVP so that  
4 the matrix can exist stably. Therefore, PVP is considered to be a suitable carrier for  
5 carotenoids having high hydrophobicity and crystallinity. Moreover, its use is  
6 considered to be more suitable for xanthophylls such as astaxanthin and lutein, which  
7 contain proton donator groups, e.g. hydroxyl group. There is limited evidence that water  
8 dispersibility of carotenoids such as  $\beta$ -carotene and lutein was improved using PVP  
9 [11,14,15].

10 In many studies, the formation of carotenoids-containing nanodispersions is  
11 conducted by emulsification-evaporation, emulsification-diffusion, and solvent-  
12 displacement techniques [16]. However, these techniques use toxic organic solvents to  
13 dissolve carotenoids in oil phase and have a concern that the solvents remain in the  
14 obtained emulsions [8,16,17]. Thus, in recent years, the formation of nanodispersions  
15 utilizing supercritical CO<sub>2</sub> (SC-CO<sub>2</sub>), which is non-toxic and easily separated from the  
16 products, has been extensively examined. The supercritical anti-solvent (SAS) process  
17 is one of the micronization methods which can be applied for preparing fine particles  
18 from various materials such as pharmaceuticals, coloring matters, biopolymers  
19 [11,18,19]. In this study, the coprecipitation of PVP and astaxanthin was carried out  
20 using the method of solution-enhanced dispersion by supercritical fluids (SEDS), which  
21 is a modified version of the SAS process [20,21]. In this process, the solution and SC-  
22 CO<sub>2</sub> are sprayed into a precipitator by a coaxial nozzle. In a typical SEDS process, an  
23 anti-solvent fluid (SC-CO<sub>2</sub>) and a solution containing compounds to be processed are  
24 injected via the nozzle into a precipitation vessel continuously, and particles are formed

1 when supersaturation of the compounds is achieved. Additionally, the particle size is  
2 easily controlled by the preparation conditions such as pressure and temperature.

3 Although there are limited number of literatures, water dispersibility of carotenoids  
4 was improved by coprecipitate formation with several hydrophilic carriers using SC-  
5 CO<sub>2</sub> as the anti-solvent [11,21–25]. For example, Prosapio et al. [11] have reported that  
6 β-carotene-containing nanoparticles with high water dispersibility could be obtained by  
7 coprecipitation of the carotenoid and PVP using SAS process. Moreover, an example of  
8 improving the water dispersibility of lycopene using β-cyclodextrin as a carrier by the  
9 solution-enhanced dispersion by SEDS process has also been reported by Nerome et al.  
10 [21]. However, to the best of our knowledge, there have been no reports about  
11 coprecipitation of astaxanthin and PVP using SC-CO<sub>2</sub> as an anti-solvent, and the  
12 previous literatures on coprecipitation of carotenoids and hydrophilic carriers using SAS  
13 or SEDS method evaluated only particle morphology, particle size, and dissolution  
14 efficiency in water of obtained coprecipitates, while carotenoid content and  
15 encapsulation efficiency of astaxanthin in the coprecipitates was not assessed  
16 [11,21–25]. Furthermore, the effect of *Z*-isomerization pre-treatment of (all-*E*)-  
17 astaxanthin was also investigated in this study (Fig. 1B–D). Since *Z*-isomers of  
18 carotenoids have higher solubility and lower crystallinity than the all-*E* isomers  
19 [26–29], the mean diameter, particle morphology, and astaxanthin content of the  
20 obtained particles would be affected. In fact, Kodama et al. [20] have reported that  
21 when lycopene was micronized by SEDS process, as the *Z*-isomer content of lycopene  
22 increased, the size of obtained particle became smaller. Additionally, since *Z*-isomers of  
23 astaxanthin have higher bioavailability [30] and antioxidant capacity [31,32] than the  
24 all-*E*-isomer, to obtain coprecipitates of PVP and *Z*-isomer-rich astaxanthin would result

1 in the improvement of the functional value. Therefore, the aim of the study is to clarify  
2 the effect of operating conditions and *Z*-isomer content of astaxanthin on coprecipitate  
3 formation of astaxanthin and PVP using SEDS process.

4

## 5 **2. Materials and methods**

### 6 *2.1. Chemicals*

7 High purity (*all-E*)-astaxanthin (synthetic) and PVP (average molecular weight  
8 10,000) were obtained by Sigma-Aldrich Co. Ltd. (Dorset, United Kingdom). High-  
9 performance liquid chromatography (HPLC)-grade methanol, acetonitrile, and  
10 dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>) were purchased from Kanto Chemical Co., Inc. (Tokyo,  
11 Japan), and HPLC-grade acetone and analytical grade ethanol were purchased from  
12 Wako Pure Chemical Industries, Ltd. (Osaka, Japan).

13

### 14 *2.2. Preparation of astaxanthin Z-isomers*

15 Astaxanthin that contains a large amount of *Z*-isomers was prepared by the thermal  
16 isomerization and filtering technique from (*all-E*)-astaxanthin described previously  
17 [20,33,34]. Briefly, (*all-E*)-astaxanthin was dissolved in CH<sub>2</sub>Cl<sub>2</sub> at a concentration of 1  
18 mg/mL and heated at 80 °C for 3 h. Then, the thermally treated astaxanthin solution was  
19 evaporated to dry under reduced pressure at 40 °C and the residue (ca. 50 mg) was  
20 suspended in 10 mL of hexane. The insoluble substances, mostly consisting of (*all-E*)-  
21 astaxanthin, were removed using a 0.2- $\mu$ m polytetrafluoroethylene (PTFE) membrane  
22 filter (DISMIC-25HP, Advantec, Tokyo), and hexane was removed under reduced  
23 pressure at 40 °C. In this study, (*all-E*)-astaxanthin, thermally *Z*-isomerized astaxanthin,  
24 and the filtered astaxanthin after thermal treatment were used as raw materials for

1 coprecipitate formation using the SEDS process.

2

### 3 *2.3. Equipment and procedure*

4 A schematic diagram of the SEDS micronization is shown in Fig. 2. The apparatus  
5 includes a chiller (CCA-1111, Tokyo Rikakikai Co., Ltd., Tokyo), two high-pressure  
6 pumps, one for CO<sub>2</sub> (PU-2086, Jasco Co., Tokyo) and the other for the astaxanthin and  
7 PVP solution (LC-20AT, Shimadzu Co., Ltd., Kyoto, Japan), a heating chamber (EI-  
8 700B, As One Co., Osaka, Japan), a coaxial nozzle with inside diameter 0.5 mm (SUS-  
9 316), a filter for collecting particles (500 nm SUS-316) placed inside a Swagelok filter  
10 housing, a back-pressure regulator (BPR; Akico Co., Ltd., Tokyo), and a wet gas meter  
11 (Shinagawa Co., Ltd., Tokyo). Liquid CO<sub>2</sub> flowing from the CO<sub>2</sub> cylinder was  
12 compressed and controlled with the high-pressure pump which was cooled with a chiller  
13 to keep CO<sub>2</sub> in a liquid state. In the heating chamber, CO<sub>2</sub> was transformed into a  
14 supercritical state by heating.

15 The coprecipitation of PVP and astaxanthin using the above apparatus was  
16 performed according to the following procedures [11,20,21]. SC-CO<sub>2</sub> was flowed to the  
17 filter at a flow rate of 15 mL/min until the desired pressure and temperature conditions  
18 were reached. The astaxanthin and PVP solution (acetone/ethanol, 19:1, v/v) were then  
19 injected at 0.1 mL/min for 1 h. At the end of each experiment, SC-CO<sub>2</sub> was pumped to  
20 flow continuously for 30 min to eliminate the remaining organic solvent from the  
21 particles. Finally, the particles were collected from the membrane filter after  
22 depressurization. The experiment was carried out at pressures of 8–15 MPa and  
23 temperatures of 40–60 °C. The contents of PVP and astaxanthin in acetone/ethanol  
24 solution were 0.73–2.94 and 0.14 mg/mL, respectively: PVP/astaxanthin ratio:

1 approximately 5:1–20:1, and the range of *Z*-isomer contents of astaxanthin were 0–  
2 66.2%. Table 1 shows the summary of experimental conditions with the results of mean  
3 diameter and astaxanthin content of the coprecipitates obtained.

#### 4 5 *2.4. SEM analysis*

6 The shape and surface characteristics of the PVP/astaxanthin coprecipitates as well  
7 as PVP and (all-*E*)-astaxanthin, which were raw materials, were observed by scanning  
8 electron microscopy (SEM; JSM-6390LV JEOL, Tokyo, Japan). The samples were  
9 sputter-coated with gold in a high-vacuum evaporator and examined using SEM at 15  
10 kV [20]. Particle size and size distributions were measured using Image J software for at  
11 least 250 particles collected at each experiment [20,21].

#### 12 13 *2.5. FT-IR analysis*

14 The characteristics of chemical structures of the PVP/astaxanthin coprecipitates as  
15 well as PVP and (all-*E*)-astaxanthin, which were raw materials, were analyzed by a  
16 Spectrum One Fourier transform infrared (FT-IR) spectrophotometer (Perkin-Elmer  
17 Ltd., Buckinghamshire, United Kingdom). The samples were placed directly in the  
18 diffuse reflectance attachment sample holder. Pre-flattening of the sample in a diamond  
19 cell was necessary prior to mounting. The spectra were measured in ATR (attenuated  
20 total reflectance) mode (golden single reflection ATR system, P/N 10500 series, Specac)  
21 at 4 cm<sup>-1</sup> resolution. The scanning wavenumber ranged from 4000 to 500 cm<sup>-1</sup> [35].

#### 22 23 *2.6. Powder XRD analysis*

24 Powder X-ray diffraction (XRD) measurements of PVP/astaxanthin coprecipitates as

1 well as intact PVP and (all-*E*)-astaxanthin were carried out on a Rigaku FR-E X-ray  
2 diffractometer. Cu K $\alpha$  radiation ( $\lambda = 1.542 \text{ \AA}$ ) was used with a beam size of  
3 approximately  $300 \mu\text{m} \times 300 \mu\text{m}$ , with a camera length of 70 mm. The powder sample  
4 was placed in a capillary tube ( $\varnothing 1.0 \text{ mm}$ ) and was irradiated with the X-ray beam  
5 without further adjustments [20].

6

### 7 *2.7. Encapsulated astaxanthin content*

8 Content of encapsulated astaxanthin in PVP was determined by measurement of  
9 the absorbance of the prepared coprecipitates at 480 nm using an UV/VIS  
10 spectrophotometer (V-550, JASCO Co., Tokyo, Japan). Before the measurement, the  
11 obtained coprecipitates were accurately weighed using an analytical balance ( $\pm 0.1 \mu\text{g}$ ,  
12 XP2UV, Mettler-Toledo, Inc., Columbus, OH, USA) and diluted with distilled water  
13 until the absorbance at the wavelength (480 nm) was between 0.3 and 1.0 absorbance  
14 units. The absorbance determined with this method is proportional to the amount of  
15 astaxanthin dispersed in solution. However, since the particles of crystalline astaxanthin  
16 are not stabilized in the suspension, they do not contribute to the absorbance determined  
17 with this method [36,37].

18

### 19 *2.7. HPLC analysis*

20 To determine *Z*-isomer content of astaxanthin, reversed-phase HPLC analysis with  
21 a C<sub>18</sub> column (STR-ODS II,  $250 \times 4.6 \text{ mm i.d.}$ , Shinwa Chemical Industries Ltd.,  
22 Kyoto, Japan) was carried out according to the method described previously [33]. The  
23 mobile phase consisted of methanol/acetonitrile/CH<sub>2</sub>Cl<sub>2</sub>/water (85:5.5:5:4.5, v/v), and  
24 the flow rate and column temperature were set at 1 mL/min and 30 °C, respectively. The

1 quantification of *Z*-isomers of astaxanthin was carried out by peak area integration at  
2 480 nm by a photodiode array detector (SPD-M10A, Shimadzu, Kyoto, Japan).  
3 Astaxanthin isomer peaks were identified according to HPLC retention times, visible  
4 spectral data, and relative intensities of the *Z*-peak at approximately 370 nm to the  
5 absorption maximum of the isomer ( $\% D_B/D_{II}$ ), as described previously [33,38,39].  
6 When determining the *Z*-isomer content in the coprecipitates, before the HPLC analysis,  
7 astaxanthin isomers were extracted by ethanol/hexane (2:3, v/v) according to the  
8 method of Yuan et al. (2008) [40]. The extracted astaxanthin was dissolve in the same  
9 solution as the mobile phase and filtered through a 0.2- $\mu$ m PTFE membrane filter. The  
10 astaxanthin *Z*-isomer content (%) was estimated as the amount of total *Z*-isomers to the  
11 amount of total astaxanthin isomers including the all-*E*-isomers.

12

### 13 **3. Results and discussion**

#### 14 *3.1. General characteristics of PVP/astaxanthin coprecipitates*

15 The characteristics of coprecipitates of PVP and (all-*E*)-astaxanthin obtained by  
16 SEDS process were assessed. The evaluation was conducted for the coprecipitates  
17 obtained at pressure of 10 MPa and temperature of 60 °C for 1 h, and 20:1 of PVP/(all-  
18 *E*)-astaxanthin ratio.

19

##### 20 *3.1.1. Particle morphology and size*

21 SEM images of the PVP/(all-*E*)-astaxanthin coprecipitates as well as intact PVP  
22 and (all-*E*)-astaxanthin are shown in Fig. 3. Before the SEDS process, PVP was white  
23 powder (Fig. S1A) and approximately 30- $\mu$ m-diameter spherical particles (Fig. 3A), and  
24 (all-*E*)-astaxanthin was dark reddish-black powder (Fig. S1B) [5] and approximately 3-

1  $\mu\text{m}$ -diameter flake-shaped crystals (Fig. 3B). On the other hand, after the SEDS process,  
2 the obtained coprecipitates was bright-red powder (Fig. S1C) and approximately 200-  
3 nm-diameter spherical particles (Fig. 3C). Prosapio et al. [11] and Nerome et al. [21]  
4 have also reported that when carotenoids such as  $\beta$ -carotene and lycopene were treated  
5 with SAS or SEDS process together with hydrophilic carriers such as PVP and  $\beta$ -  
6 cyclodextrin, nano-level spherical particles were obtained.

7

### 8 *3.1.2. Solubility in water*

9 The solubility in water of the obtained coprecipitates were investigated using the  
10 UV/VIS spectrophotometer. The evaluations were conducted for PVP, (all-*E*)-  
11 astaxanthin, and the coprecipitates which were dissolved in water to be the same  
12 concentration (wt%). Fig. 4A shows the absorption wavelengths of the samples in water.  
13 The coprecipitate had the absorbance in the range of 400 to 600 nm, which was  
14 astaxanthin-specific absorbance [33,38,39]. On the other hand, water-dissolved (all-*E*)-  
15 astaxanthin had no absorbance. The compound-specific absorbance can be observed  
16 when the compound disperses in the solution [36,37]. Therefore, this results indicated  
17 that water-soluble PVP/astaxanthin inclusion complex had been successfully formed  
18 using the SEDS process. Moreover, since the absorbance determined by UV/VIS  
19 spectrophotometer is proportional to the amount of astaxanthin dispersed in solution and  
20 only astaxanthin encapsulated by PVP was detected [36,37], the quantification of  
21 astaxanthin was conducted by using the method in this study.

22

### 23 *3.1.3. FT-IR analysis*

24 Fig. 4B shows the FT-IR spectra of PVP/astaxanthin coprecipitates as well as intact

1 PVP and (all-*E*)-astaxanthin. As for PVP and (all-*E*)-astaxanthin, the same spectra  
2 patterns were observed in previous studies [41,42]. The spectrum of the coprecipitates  
3 showed the same pattern with that of intact PVP: although IR spectrum of pure  
4 astaxanthin showed the characteristics of very strong absorption band at  $1547\text{ cm}^{-1}$  for  
5 stretching vibration of C=C in the hexatomic ring and  $974\text{ cm}^{-1}$  for C–H stretching  
6 vibration in C, C conjugate system, those absorption band were disappeared. This is  
7 probably because (all-*E*)-astaxanthin was encapsulated in PVP. In fact, a number of  
8 studies have reported that when compounds were encapsulated in carriers including  
9 PVP, the FT-IR spectra shows the same pattern as those [42,43].

10

#### 11 *3.1.4. Powder XRD analysis*

12 Fig. 4C shows the powder XRD patterns of PVP/astaxanthin coprecipitates as well  
13 as intact PVP and (all-*E*)-astaxanthin. As for PVP and (all-*E*)-astaxanthin, the same  
14 spectra patterns as previous studies were observed [44–46]. On the other hand, as for  
15 the coprecipitates, the spectra peculiar to (all-*E*)-astaxanthin disappeared completely  
16 and showed PVP-like XRD patterns: two broad peaks were observed at a diffraction  
17 angle  $2\theta$  value of  $10\text{--}25^\circ$ . This result has observed in previous studies which prepared  
18 coprecipitation by supercritical antisolvent process using PVP as a carrier [45,46], and it  
19 indicated that (all-*E*)-astaxanthin formed complexes with PVP.

20

#### 21 *3.2. Effect of pressure*

##### 22 *3.2.1. Particle morphology and size*

23 The effect of operating pressure on particle morphology and size of obtained  
24 coprecipitates was investigated by SEM analysis. The obtained particles were spherical

1 and there were no significant differences in particle morphology at any pressure (Fig.  
2 S2). The mean particle size was approximately 150 nm at 8 and 10 MPa, while when  
3 processing at 15 MPa, the mean particle size increased slightly (175 nm) and the  
4 particle size distribution expanded (Table 1, Fig. 5A). Generally, increasing the  
5 operating pressure, the obtained particle size become smaller due to increase of anti-  
6 solvent (SC-CO<sub>2</sub>) density: fast mixing and mass transfer at higher densities lead to  
7 smaller particles [46]. Several studies using PVP under SAS process has been also  
8 reported that as the operating pressure increased, the particle size decreases [11,45,47].  
9 However, as the anti-solvent density increases, the diffusivity of the organic solvent  
10 decreases and the mass transfer and mixing would slow down. That may result in  
11 increment of the particle size [46,48]. As an example, Uzun et al. [44] reported that  
12 when preparing PVP/cefuroxime axetil inclusion complex by SAS process from the  
13 methanol solution, the obtained particle size increased by increasing the operating  
14 pressure.

15

### 16 *3.2.2. Encapsulated astaxanthin content*

17 The encapsulated astaxanthin content corresponding to operating pressure was  
18 determined using an UV/VIS spectrophotometer. When the coprecipitation of PVP and  
19 (all-*E*)-astaxanthin by SEDS process was performed at temperature of 40 °C and  
20 pressures of 8, 10, 15 MPa, the astaxanthin content of obtained particles were 0.51,  
21 0.33, and 0.07%, respectively. It seemed that the lower the pressure resulted to the  
22 higher the astaxanthin content in the coprecipitation. It has been known that operating  
23 pressure may give effects on the CO<sub>2</sub> density in supercritical condition and the viscosity  
24 of solution. It also affected to the mass transfer of solutes, in particular, organic solvents

1 having low molecular weight, in SC-CO<sub>2</sub> during precipitation process. Namely, as the  
2 operating pressure reduced, the mass transfer of the organic solvents increased and they  
3 immediately diffused into SC-CO<sub>2</sub>. As the result, PVP and astaxanthin might rapidly  
4 form complexes and thus the recovery of astaxanthin increased [49,50]. Although the  
5 astaxanthin content in the particles was highest at pressure of 8 MPa, here, the  
6 subsequent experiments were performed at pressure of 10 MPa. Martin et al. [51]  
7 conducted experiments for coprecipitation of carotenoids and bio-polymers with the  
8 supercritical anti-solvent process. They reported that the carotenoid particles were  
9 covered partially by polymer as a coprecipitator when the experiments were performed  
10 at pressure of 8 MPa. Hence, in this work, the operating pressure of experiments were  
11 fixed at 10 MPa.

12 On the other hand, since PVP/astaxanthin ratio in the starting solution was 20:1, if  
13 all PVP and astaxanthin precipitated by this process, astaxanthin content should be  
14 approximately 5%. However, the content was significantly lower than 5%. This is  
15 probably because astaxanthin has much higher solubility in SC-CO<sub>2</sub> than PVP (about  
16 100 times higher) [52,53], i.e. since a large amount of astaxanthin was the dissolution  
17 state in SC-CO<sub>2</sub>, it passed through the particulate collection filter and/or astaxanthin  
18 was extracted from coprecipitates in the 30 min of organic solvent removal process.

19

### 20 *3.3. Effect of temperature*

#### 21 *3.3.1. Particle morphology and size*

22 The influence of operating temperature on particle morphology and size of  
23 PVP/astaxanthin coprecipitates was evaluated. The temperatures were varied between  
24 40–60 °C. All the obtained particles were spherical, and there was no significant

1 difference in particle morphology at any temperatures at operating pressure of 10 MPa  
2 (Fig. S3). On the other hand, increasing the operating temperature, the particle size  
3 increased and particle size distribution expanded (Table. 1, Fig. 5B). Generally, in SAS  
4 precipitation, as the temperature increases, since the density of SC-CO<sub>2</sub> decreases, the  
5 mass transfer rate decreases. In accordance with that, the supersaturation ratio decreased  
6 and larger particles were formed [46]. This tendency was also observed in other studies  
7 of SAS coprecipitation using PVP as a carrier [45,47].

### 9 *3.3.2. Encapsulated astaxanthin content*

10 When the SEDS process was performed at temperatures of 40, 50, 60 °C and  
11 pressure of 10 MPa, the astaxanthin content in the obtained particles were 0.33, 0.49,  
12 and 1.43%, respectively. It showed that the higher operating temperature resulted in the  
13 higher astaxanthin content of the obtained coprecipitates. As with operating pressure,  
14 the temperature also gave effects on the CO<sub>2</sub> density in supercritical condition and the  
15 viscosity of solution, and consequently, it affected to the mass transfer of the solutes, in  
16 particular organic solvents. Raising the operating temperature, the mass transfer of  
17 organic solvents increased, they immediately diffused into SC-CO<sub>2</sub>, and then PVP and  
18 astaxanthin might rapidly form complexes. As the result, it is considered that the  
19 recovery of astaxanthin increased [49,50]. Moreover, the nucleation rate of solute also  
20 increased with increasing operating temperature at a constant operating pressure.

### 22 *3.4. Effect of PVP/astaxanthin ratio*

#### 23 *3.4.1. Particle morphology and size*

24 The obtained particles were spherical, and there was no significant difference in

1 particle morphology at any PVP/astaxanthin ratio at pressure of 10 MPa and  
2 temperature of 60 °C (Fig. S4). On the other hand, as the PVP ratio decreased, the  
3 particle size decreased and particle size distribution was narrow (Fig. 6A). This  
4 tendency was also observed in the other studies of SAS coprecipitation using PVP as a  
5 carrier [45,48]. It is considered that the supersaturation ratio of PVP/astaxanthin  
6 coprecipitates in SC-CO<sub>2</sub> increased by decreasing PVP ratio so that the particle size  
7 decreased.

8

### 9 *3.4.2. Encapsulated astaxanthin content*

10 In the case of processing in the PVP/astaxanthin ratio of 20:1, 10:1, and 5:1 under  
11 the operating conditions at temperature of 60 °C and pressure of 10 MPa, the  
12 astaxanthin content of the coprecipitates were 1.43, 3.91, and 3.90%, respectively. It  
13 showed that when the PVP/astaxanthin ratio as a feed solution was 10:1, the highest of  
14 astaxanthin content in particles products was found. Regarding to the active compounds  
15 encapsulation, essentially, there are two tendencies: the active compounds can be coated  
16 by a thin layer of polymer or the active compounds and polymer can be precipitated to  
17 produce fine particles with the active compounds impregnated into polymeric particles  
18 [50]. Generally, the active compounds coated by polymer is better when the polymer  
19 concentration is increased and a shift in the polymer concentration may lead to change  
20 morphology of particles. However, as shown above, there was no significant difference  
21 in particle morphology at any PVP/astaxanthin ratio between 5:1 and 10:1.  
22 Additionally, when the ratio was 10:1, the amount of coprecipitates obtained was  
23 approximately 1.3 times higher than 5:1 of the ratio. Based on the result, the subsequent  
24 experiments were performed in the PVP/astaxanthin ratio of 10:1, which has the highest

1 recovery of astaxanthin.

2

### 3 *3.5. Effect of Z-isomer content of astaxanthin*

#### 4 *3.5.1. Profile of astaxanthin isomers obtained by thermal isomerization and filtration*

5 Ample studies have demonstrated that (all-*E*)-carotenoids easily isomerized to the  
6 *Z*-isomers in organic solvents by heating [20,26,33]. (all-*E*)-Astaxanthin was also  
7 isomerized to the *Z*-isomers by heating at temperature of 80 °C in CH<sub>2</sub>Cl<sub>2</sub> for 3 h in this  
8 study. After the heating, the total *Z*-isomer content reached 39.4%. Furthermore, after  
9 the thermally treated astaxanthin was dissolved in hexane and filtered by a 0.2- $\mu$ m  
10 PTFE membrane filter, the total *Z*-isomer content further increased to 66.2%. This was  
11 because *Z*-isomers of carotenoids were more soluble in solvents than the (all-*E*)-isomers  
12 [20,26–28], i.e. since (all-*E*)-astaxanthin was low solubility in hexane, the isomer was  
13 removed by the filtration. The reversed-phase HPLC charts of (all-*E*)-astaxanthin and  
14 the thermally *Z*-isomerized and filtered samples are shown in Fig. 7. Peaks in Fig. 7  
15 were tentatively identified by those absorption spectra and relative intensities of the *Z*-  
16 peak (%  $D_B/D_{II}$ ) referring to literatures (Fig. S5 and Table S1) [33,38,39]. As with  
17 previous studies of thermal isomerization of (all-*E*)-astaxanthin in organic solvents  
18 [33,38], (9*Z*)- and (13*Z*)-astaxanthin emerged. The coprecipitation of PVP and  
19 astaxanthin containing 39.4% and 66.2% of the *Z*-isomers was performed by SEDS  
20 process.

21

#### 22 *3.5.2. Particle morphology and size*

23 The effect of *Z*-isomer content of astaxanthin on particle morphology and size of  
24 obtained coprecipitates was investigated by SEM analysis. The obtained particles were

1 spherical, and when using astaxanthin having the highest *Z*-isomer content (66.2%), a  
2 small number of agglomerated particles were observed (Fig. S6). Thus, although the  
3 mean particle size did not have a big difference by the *Z*-isomer content, when 66.2% of  
4 *Z*-isomer content astaxanthin was used as the raw material, the particle size distribution  
5 expanded slightly (Fig. 6B). The physical properties such as solubility and crystallinity  
6 of carotenoids significantly changed by the *E/Z* isomerization [26–29]. Those changes  
7 would affect the particle size and particle size distribution of the coprecipitates with  
8 PVP. In fact, Prosapio et al. [54] showed that components difference affected the  
9 particle size of coprecipitates with PVP obtained by SAS precipitation.

### 11 3.5.3. Encapsulated astaxanthin concentration

12 When using (all-*E*)-astaxanthin and astaxanthin of which the *Z*-isomer contents  
13 were 39.4% and 66.2% as raw materials of the PVP/astaxanthin coprecipitation by  
14 SEDS process at pressure of 10 MPa and temperature of 60 °C, the astaxanthin content  
15 of obtained particles were 3.91, 3.78, and 3.56%, respectively, and the total *Z*-isomer  
16 contents were 8.2, 40.2, 58.7% (Fig. S7), respectively. Although it was a slight change,  
17 the higher the *Z*-isomer content in the raw material, the lower the astaxanthin content in  
18 the obtained coprecipitates. *Z*-Isomers of carotenoids are more soluble in solvents  
19 including SC-CO<sub>2</sub> than the all-*E*-isomer [26–28]. Therefore, it is considered that since  
20 the supersaturation ratio of astaxanthin in SC-CO<sub>2</sub> increased by the *Z*-isomerization pre-  
21 treatment, the efficiency of coprecipitation formation decreased, or in the solvent  
22 removal process after coprecipitation formation, several *Z*-isomers including in the  
23 coprecipitates was extracted due to the high solubility in SC-CO<sub>2</sub>. However, by using  
24 PVP as a carrier, most of astaxanthin *Z*-isomers were successfully included in it and

1 formed nanocoprecipitates. Our previous study [20] have attempted to obtain *Z*-isomer-  
2 rich lycopene particles from lycopene containing a large amount of the *Z*-isomer by  
3 SEDS precipitation, though since the *Z*-isomers had high solubility in SC-CO<sub>2</sub>, the  
4 particles could not be formed. As with other carotenoids such as lycopene [55–57], *Z*-  
5 isomers of astaxanthin have higher bioavailability [30] and antioxidant capacity [31,32]  
6 than the all-*E*-isomer. Thus, although the encapsulation efficiency of astaxanthin is  
7 slightly lowered, the use of *Z*-isomer-rich astaxanthin as the raw material for  
8 PVP/astaxanthin coprecipitation by SEDS process would result in improvement the  
9 functionality of the coprecipitates.

10

#### 11 **4. Conclusion**

12 Water-soluble PVP/astaxanthin nanocoprecipitates were successfully prepared by  
13 SEDS precipitation. It was found that the operating pressure, temperature,  
14 PVP/astaxanthin ratio, and *Z*-isomer content of astaxanthin affect the particle size  
15 and/or astaxanthin content in the coprecipitates: increasing the pressure in the range of  
16 8–15 MPa, the astaxanthin content decreased; increasing the temperature in the range of  
17 40–60 °C, the particle size and the astaxanthin content increased; increasing the PVP  
18 ratio for astaxanthin in the range of 5:1–20:1 the particle size increased and when 10:1  
19 of the ratio, the astaxanthin content was the highest; increasing the *Z*-isomer content of  
20 astaxanthin in the range of 0–66.2%, the astaxanthin content decreased. Therefore, it is  
21 considered that fine and high astaxanthin content water-soluble particles can be  
22 obtained by optimizing these parameters. Furthermore, it is known that since the *Z*-  
23 isomers of carotenoids have high solubility in solvents including SC-CO<sub>2</sub>, preparation  
24 of the fine particles by anti-solvent processing is difficult. However, by the

1 coprecipitation with PVP, the fine particles rich in *Z*-isomers of astaxanthin successfully  
2 obtained. As the *Z*-isomers of astaxanthin have higher bioavailability and antioxidant  
3 capacity than the all-*E*-isomer, the use of *Z*-isomers of astaxanthin as the raw material  
4 of PVP/astaxanthin coprecipitation would improve the functionality of the coprecipitate.

5

## 6 **References**

- 7 [1] T. Maoka, T. Carotenoids in marine animals. *Mar. Drugs* 9 (2011) 278–293.
- 8 [2] N.I. Krinsky, E.J. Johnson, Carotenoid actions and their relation to health and  
9 disease. *Mol. Asp. Med.* 26 (2005) 459–516.
- 10 [3] X.R. Xu, Z.Y. Zou, Y.M. Huang, X. Xiao, L. Ma, X.M. Lin, Serum carotenoids in  
11 relation to risk factors for development of atherosclerosis. *Clin. Biochem.* 45 (2012)  
12 1357–1361.
- 13 [4] A. Ouchi, K. Aizawa, Y. Iwasaki, T. Inakuma, J. Terao, S. Nagaoka, K. Mukai,  
14 Kinetic study of the quenching reaction of singlet oxygen by carotenoids and food  
15 extracts in solution. Development of a singlet oxygen absorption capacity (SOAC) assay  
16 method, *J. Agric. Food Chem.* 58 (2010) 9967–9978.
- 17 [5] J. Dhankhar, S.S. Kadian, A. Sharma, Astaxanthin: A potential carotenoid. *Int. J.*  
18 *Pharm. Sci. Res.* 3 (2012) 1246–1259.
- 19 [6] G. Hussein, U. Sankawa, H. Goto, K. Matsumoto, H. Watanabe, H. Astaxanthin, a  
20 carotenoid with potential in human health and nutrition. *J. Nat. Prod.* 69 (2006)  
21 443–449.
- 22 [7] A. Spornath, A. Aserin, Microemulsions as carriers for drugs and nutraceuticals.  
23 *Adv. Colloid Interface Sci.* 128 (2006) 47–64.
- 24 [8] N. Anarjan, C.P. Tan, Effects of selected polysorbate and sucrose ester emulsifiers

1 on the physicochemical properties of astaxanthin nanodispersions. *Molecules* 18 (2013)  
2 768–777.

3 [9] L. Salvia-Trujillo, C. Qian, O. Martín-Belloso, D.J. McClements, Influence of  
4 particle size on lipid digestion and  $\beta$ -carotene bioaccessibility in emulsions and  
5 nanoemulsions. *Food Chem.* 141 (2013) 1472–1480.

6 [10] R. Vishwanathan, T.A. Wilson, R.J. Nicolosi, Bioavailability of a nanoemulsion of  
7 lutein is greater than a lutein supplement. *Nano Biomed. Eng.* 1 (2009) 38–49.

8 [11] V. Prosapio, E. Reverchon, I. De Marco, Coprecipitation of  
9 polyvinylpyrrolidone/ $\beta$ -carotene by supercritical antisolvent processing. *Ind. Eng.*  
10 *Chem. Res.* 54 (2015) 11568–11575.

11 [12] G.A. Ledet, R.A. Graves, E.Y. Glotser, T.K. Mandal, L.A. Bostanian, Preparation  
12 and in vitro evaluation of hydrophilic fenretinide nanoparticles. *Int. J. Pharm.* 479  
13 (2015) 329–337.

14 [13] M.P. Oth, A.J. Moes, Enhanced in vitro release of indomethacin from non-aqueous  
15 suspensions using indomethacin-polyvinylpyrrolidone coprecipitate. *Int. J. Pharm.* 24  
16 (1985) 275–286.

17 [14] C. Zhao, H. Cheng, P. Jiang, Y. Yao, J. Han, Preparation of lutein-loaded particles  
18 for improving solubility and stability by polyvinylpyrrolidone (PVP) as an emulsion-  
19 stabilizer. *Food Chem.* 156 (2014) 123–128.

20 [15] W. Liu, J. Wang, M. Li, W. Tang, J. Han, Molecular mechanism of the protective  
21 effect of monomer polyvinylpyrrolidone on antioxidants—experimental and  
22 computational studies. *SAR QSAR Environ. Res.* 27 (2016) 1015–1027.

23 [16] D. Horn, J. Rieger, Organic nanoparticles in the aqueous phase—theory,  
24 experiment, and use. *Angew. Chem. Int. Ed.* 40 (2001) 4330–4361.

- 1 [17] C.P. Tan, M. Nakajima,  $\beta$ -Carotene nanodispersions: preparation, characterization  
2 and stability evaluation. *Food Chem.* 92 (2005) 661–671.
- 3 [18] I. De Marco, V. Prosapio, F. Cice, E. Reverchon, Use of solvent mixtures in  
4 supercritical antisolvent process to modify precipitates morphology: Cellulose acetate  
5 microparticles. *J. Supercrit. Fluids* 83 (2013) 153–160.
- 6 [19] Y. Wang, Y. Wang, J. Yang, R. Pfeffer, R., Dave, B. Michniak, The application of a  
7 supercritical antisolvent process for sustained drug delivery. *Powder Technol.* 164  
8 (2006) 94–102.
- 9 [20] T. Kodama, M. Honda, R. Takemura, T. Fukaya, C. Uemori, H. Kanda, M. Goto,  
10 Effect of the Z-isomer content on nanoparticle production of lycopene using solution-  
11 enhanced dispersion by supercritical fluids (SEDS). *J. Supercrit. Fluids* 133 (2018) 291–  
12 296.
- 13 [21] H. Nerome, S. Machmudah, R. Fukuzato, T. Higashiura, Y.S. Youn, Y.W. Lee, M.  
14 Goto, Nanoparticle formation of lycopene/ $\beta$ -cyclodextrin inclusion complex using  
15 supercritical antisolvent precipitation, *J. Supercrit. Fluids* 83 (2013) 97–103.
- 16 [22] E. Franceschi, A.M. De Cesaro, M. Feiten, S.R.S Ferreira, C. Dariva, M.H. Kunita,  
17 A.F. Rubire, E.C. Muniz, M.L. Corazza, J.V. Oliveira, Precipitation of  $\beta$ -carotene and  
18 PHBV and co-precipitation from SEDS technique using supercritical CO<sub>2</sub>. *J. Supercrit.*  
19 *Fluids* 47 (2008) 259–269.
- 20 [23] A. Martín, F. Mattea, L. Gutiérrez, F. Miguel, M.J. Cocero, Co-precipitation of  
21 carotenoids and bio-polymers with the supercritical anti-solvent process. *J. Supercrit.*  
22 *Fluids* 41 (2007) 138–147.

- 1 [24] F. Miguel, A. Martín, F. Mattea, M.J. Cocero, Precipitation of lutein and co-  
2 precipitation of lutein and poly-lactic acid with the supercritical anti-solvent process.  
3 Chem. Eng. Proc.: Proc. Intensif. 47 (2008) 1594–1602.
- 4 [25] W.L. Priamo, A.M. de Cezaro, S.R. Ferreira, J.V. Oliveira, Precipitation and  
5 encapsulation of  $\beta$ -carotene in PHBV using carbon dioxide as anti-solvent. J. Supercrit.  
6 Fluids 54 (2010) 103–109.
- 7 [26] K. Murakami, M. Honda, R. Takemura, T. Fukaya, M. Kubota, Wahyudiono, H.  
8 Kanda, M. Goto, The thermal *Z*-isomerization-induced change in solubility and physical  
9 properties of (all-*E*)-lycopene, Biochem. Biophys. Res. Commun. 491 (2017) 317–322.
- 10 [27] M. Honda, Y. Watanabe, K. Murakami, R. Takemura, T. Fukaya, Wahyudiono, H.  
11 Kanda, M. Goto, Thermal isomerization pre-treatment to improve lycopene extraction  
12 from tomato pulp, LWT-Food Sci. Technol. 86 (2017) 69–75.
- 13 [28] M. Honda, Y. Watanabe, K. Murakami, N.N. Hoang, H. Kanda, M. Goto, Enhanced  
14 lycopene extraction from gac (*Momordica cochinchinensis* Spreng.) by the *Z*-  
15 isomerization induced with microwave irradiation pre-treatment. Eur. J. Lipid Sci.  
16 Technol. 1700293 (2018) 1–8.
- 17 [29] J. Hempel, C.N. Schädle, S. Leptihn, R. Carle, R.M. Schweiggert, Structure related  
18 aggregation behavior of carotenoids and carotenoid esters. J. Photochem. Photobiol. A  
19 Chem. 317 (2016) 161–174.
- 20 [30] C. Yang, H. Zhang, R. Liu, H. Zhu, L. Zhang, R. Tsao, Bioaccessibility, cellular  
21 uptake, and transport of astaxanthin isomers and their antioxidative effects in human  
22 intestinal epithelial caco-2 cells. J. Agric. Food Chem. 65 (2017) 10223–10232.
- 23 [31] C. Yang, L. Zhang, H. Zhang, Q. Sun, R. Liu, J. Li, L. Wu, R. Tsao, Rapid and  
24 efficient conversion of all-*E*-astaxanthin to 9*Z*- and 13*Z*-isomers and assessment of their

1 stability and antioxidant activities. J. Agric. Food Chem. 65 (2017) 818–826.

2 [32] X. Liu, T. Osawa, *Cis* astaxanthin and especially 9-*cis* astaxanthin exhibits a higher  
3 antioxidant activity *in vitro* compared to the all-*trans* isomer. Biochem. Biophys. Res.  
4 Commun. 357 (2007) 187–193.

5 [33] J.P. Yuan, F. Chen, Isomerization of *trans*-astaxanthin to *cis*-isomers in organic  
6 solvents. J. Agric. food Chem. 47 (1999) 3656–3660.

7 [34] M. Honda, T. Kudo, T. Kuwa, T. Higashiura, T. Fukaya, Y Inoue, C. Kitamura, M.  
8 Takehara, Isolation and spectral characterization of thermally generated multi-*Z*-isomers  
9 of lycopene and the theoretically preferred pathway to di-*Z*-isomers. Biosci. Biotechnol.  
10 Biochem. 81 (2017) 365–371.

11 [35] S. Machmudah, Q.Y.A. Shiddiqi, A.D. Kharsma, Widiyastuti, Wahyudiono, H.  
12 Kanda, S. Winardi, M. Goto, Subcritical water extraction of xanthone from mangosteen  
13 (*Garcinia Mangostana Linn*) pericarp. J. Adv. Chem. Eng. 5 (2015) 1–6.

14 [36] A. Tachaprutinun, T. Udomsup, C. Luadthong, S. Wanichwecharungruang,  
15 Preventing the thermal degradation of astaxanthin through nanoencapsulation. Int. J.  
16 Pharm. 374 (2009) 119–124.

17 [37] E. de Paz, Á. Martín, E. Mateos, M.J. Cocero, Production of water-soluble  $\beta$ -  
18 carotene micellar formulations by novel emulsion techniques. Chem. Eng. Proc.: Proc.  
19 Intensif. 74 (2013) 90–96.

20 [38] L. Zhao, F. Chen, G. Zhao, Z. Wang, X. Liao, X. Hu, Isomerization of *trans*-  
21 astaxanthin induced by copper (II) ion in ethanol. J. Agric. food Chem. 53 (2005) 9620–  
22 9623.

23 [39] C. Yang, L. Zhang, H. Zhang, Q. Sun, R. Liu, J. Li, L. Wu, R. Tsao, Rapid and  
24 efficient conversion of all-*E*-astaxanthin to 9*Z*-and 13*Z*-isomers and assessment of their

- 1 stability and antioxidant activities. *J. Agric. food Chem.* 65 (2017) 818–826.
- 2 [40] Y. Yuan, Y. Gao, J. Zhao, L. Mao, Characterization and stability evaluation of  $\beta$ -  
3 carotene nanoemulsions prepared by high pressure homogenization under various  
4 emulsifying conditions. *Food Res. Int.* 41 (2008) 61–68.
- 5 [41] K.M. Koczkur, S. Mourdikoudis, L. Polavarapu, S.E. Skrabalak,  
6 Polyvinylpyrrolidone (PVP) in nanoparticle synthesis. *Dalton Trans.* 44 (2015)  
7 17883–17905.
- 8 [42] S. Dong, Y. Huang, R. Zhang, Z. Lian, S. Wang, Y. Liu, Inclusion complexes of  
9 astaxanthin with hydroxypropyl- $\beta$ -cyclodextrin: Parameters optimization, spectroscopic  
10 profiles, and properties. *Eur. J. Lipid Sci. Technol.* 116 (2014) 978–986.
- 11 [43] C. Yuan, Z. Jin, X. Xu, Inclusion complex of astaxanthin with hydroxypropyl- $\beta$ -  
12 cyclodextrin: UV, FTIR,  $^1\text{H}$  NMR and molecular modeling studies. *Carbohydr. Polym.*  
13 89 (2012) 492–496.
- 14 [44] H.L. Hong, Q.L. Suo, L.M. Han, C.P. Li, Study on precipitation of astaxanthin in  
15 supercritical fluid. *Powder Technol.* 191 (2009) 294–298.
- 16 [45] V. Prosapio, I. De Marco, M. Scognamiglio, E. Reverchon, Folic acid-PVP  
17 nanostructured composite microparticles by supercritical antisolvent precipitation.  
18 *Chem. Eng. J.* 277 (2015) 286–294.
- 19 [46] İ.N., Uzun, O., Sipahigil, S., Dinçer, Coprecipitation of cefuroxime axetil–PVP  
20 composite microparticles by batch supercritical antisolvent process. *J. Supercrit. Fluids*  
21 55 (2011) 1059–1069.
- 22 [47] J. Park, W. Cho, H. Kang, B.B.J. Lee, T.S. Kim, S.J. Hwang, Effect of operating  
23 parameters on PVP/tadalafil solid dispersions prepared using supercritical anti-solvent  
24 process. *J. Supercrit. Fluids* 90 (2014) 126–133.

- 1 [48] A. Gokhale, B. Khusid, R.N. Dave, R. Pfeffer, Effect of solvent strength and  
2 operating pressure on the formation of submicrometer polymer particles in supercritical  
3 microjets. *J. Supercrit. Fluids* 43 (2007) 341–356.
- 4 [49] M. Kalani, R. Yunus, Application of supercritical antisolvent method in drug  
5 encapsulation: a review. *Int. J. Nanomed.* 6 (2011) 1429–1442.
- 6 [50] J.I.N. Heyang, X.I.A. Fei, C. Jiang, Z.H.A.O. Yaping, H.E. Lin, Nanoencapsulation  
7 of lutein with hydroxypropylmethyl cellulose phthalate by supercritical antisolvent.  
8 *Chin. J. Chem. Eng.* 17 (2009) 672–677.
- 9 [51] A. Martin, F. Mattea, L. Gutierrez, F. Miguel, M.J. Cocero, Co-precipitation of  
10 carotenoids and bio-polymers with the supercritical anti-solvent process. *J. Supercrit.*  
11 *Fluids* 41 (2007) 138–147.
- 12 [52] J.S. Jin, C.W. Chang, J. Zhu, H. Wu, Z.T. Zhang, Solubility of poly  
13 (vinylpyrrolidone) with different molecular weights in supercritical carbon dioxide. *J.*  
14 *Chem. Eng. Data* 60 (2015) 3397–3403.
- 15 [53] H.S. Youn, M.K. Roh, A. Weber, G.T. Wilkinson, B.S. Chun, Solubility of  
16 astaxanthin in supercritical carbon dioxide. *Kor. J. Chem. Eng.* 24 (2007) 831–834.
- 17 [54] V. Prosapio, I. De Marco, E. Reverchon, PVP/corticosteroid microspheres  
18 produced by supercritical antisolvent coprecipitation. *Chem. Eng. J.* 292 (2016)  
19 264–275.
- 20 [55] A.C. Boileau, N.R. Merchen, K. Wasson, C.A. Atkinson, J.W. Erdman, *Cis-*  
21 *lycopene is more bioavailable than trans-lycopene in vitro and in vivo in lymph-*  
22 *cannulated ferrets. J. Nutr.* 129 (1999) 1176–1181.
- 23 [56] N.Z. Unlu, T. Bohn, D.M. Francis, H.N. Nagaraja, S.K. Clinton, S.J. Schwartz,  
24 *Lycopene from heat-induced cis-isomer-rich tomato sauce is more bioavailable than*

- 1 from all-*trans*-rich tomato sauce in human subjects. *Brit. J. Nutr.* 98 (2007) 140–146.
- 2 [57] L. Müller, P. Goupy, K. Fröhlich, O. Dangles, C. Caris-Veyrat, V. Böhm,
- 3 Comparative study on antioxidant activity of lycopene (*Z*)-isomers in different assays. *J.*
- 4 *Agric. food Chem.* 59 (2011) 4504–4511.
- 5

## Figure captions

**Fig. 1.** Chemical structures of (A) polyvinylpyrrolidone (PVP) and typical astaxanthin isomers: (B) (all-*E*)-astaxanthin; (C) (9*Z*)-astaxanthin; (D) (13*Z*)-astaxanthin.

**Fig. 2.** Schematic diagram of the SEDS process.

**Fig. 3.** SEM images of intact (A) PVP and (B) (all-*E*)-astaxanthin, and PVP/(all-*E*)-astaxanthin (20:1) coprecipitates obtained by SEDS process at temperature of 60 °C and pressures of 10 MPa.

**Fig. 4.** (A) Absorption spectra, (B) FT-IR spectra, and (C) XRD patterns of raw materials and PVP/(all-*E*)-astaxanthin (20:1) coprecipitates obtained by SEDS process at temperature of 60 °C and pressures of 10 MPa.

**Fig. 5.** Particle size distributions of PVP/(all-*E*)-astaxanthin (20:1) coprecipitates obtained by SEDS process (A) at temperature of 40 °C and various pressure, and (B) at pressures of 10 MPa and various temperature.

**Fig. 6.** Particle size distributions of (A) PVP/(all-*E*)-astaxanthin (various ratio) coprecipitates and (B) PVP/various *Z*-isomer content of astaxanthin (10:1) coprecipitates by SEDS process at temperature of 60 °C and pressures of 10 MPa.

**Fig. 7.** Reversed-phase HPLC chromatograms of (A) (all-*E*)-astaxanthin, (B) thermally treated astaxanthin at 80 °C for 8 h, and (C) the filtered astaxanthin. (9*Z*)- and (13*Z*)-Astaxanthin designated in the chromatograms were identified according to previous

studies [33,38,39].

**Fig. 1**





Fig. 2



**Fig. 3**







Fig. 4




**Fig. 5**



**Fig. 6**



**Fig. 7**



**Table 1**

Summery of SEDS experimental conditions.

No.	Pressure (MPa)	Temperature (°C)	PVP/astaxanthin ratio (w/w) <sup>a</sup>	Z-isomer content (%) <sup>b</sup>	Mean diameter (nm)	Astaxanthin content (%) <sup>c</sup>
1	8	40	20:1	–	152.7	0.51
2	10	40	20:1	–	132.6	0.33
3	15	40	20:1	–	175.0	0.07
4	10	50	20:1	–	174.4	0.49
5	10	60	20:1	–	203.1	1.43
6	10	60	10:1	–	124.8	3.91
7	10	60	5:1	–	99.1	3.90
8	10	60	10:1	39.4	105.6	3.78
9	10	60	10:1	66.2	141.7	3.56

<sup>a</sup> PVP and astaxanthin were dissolved in acetone/ethanol (19:1, v/v).<sup>b</sup> Total Z-isomer content of astaxanthin. –, not detected substantially.<sup>c</sup> Astaxanthin content in obtained PVP/astaxanthin coprecipitates by SEDS process.